Myelodysplastic Syndrome (MDS) Pipeline Assessment, 2023 | In-depth Insights Into the Emerging Therapies, Clinical and Non-Clinical Trials, Treatment Algorithm, and Key Players by DelveInsight

As per DelveInsight, the Myelodysplastic Syndrome (MDS) therapeutics market is anticipated to transform immensely in the coming years owing to the intense research and development (R&D) activities by the major pharmaceutical companies and the launch of emerging therapies in the market.

It is observed that patients with Myelodysplastic Syndrome collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML. Despite the availability of approved therapies, the remission or progression of Myelodysplastic Syndrome is high, which is currently a high unmet medical need. Current therapy options, excluding stem cell transplant, may prolong and improve the quality of life but are not curative. To improve the treatment scenario, globally, several key companies are actively working in the Myelodysplastic Syndrome therapeutics market.

Some of the emerging drugs in the Myelodysplastic Syndrome (MDS) market include Guadecitabine/SGI-110 (Astex Pharmaceuticals), Rigosertib (Onconova Therapeutics), APR-246 (Aprea Therapeutics), and others. The launch of emerging therapies is anticipated to transform Myelodysplastic Syndrome treatment scenario in the coming years.

"Myelodysplastic Syndrome (MDS) Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Myelodysplastic Syndrome Pipeline Analysis
The report provides insights into:
● The report provides detailed insights into the key companies that are developing therapies in the Myelodysplastic Syndrome Market.
● The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome treatment.
● It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
● It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
● Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Myelodysplastic Syndrome market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:
● Late-stage products (Phase III)
● Mid-stage products (Phase II)
● Early-stage product (Phase I)
● Pre-clinical and Discovery stage candidates
● Discontinued & Inactive candidates

Myelodysplastic Syndrome - Major Mechanism of Action (MOA) Types:
● Interleukin 8A,8B Receptor Antagonists
● HAVCR2 Protein Inhibitors
● Cytidine Deaminase Inhibitors
● TGF-beta superfamily Protein Inhibitors

The Leading Companies in the Myelodysplastic Syndrome Therapeutics Market Include:
● Celyad
● Aprea Therapeutics
● Astex Pharmaceuticals
● Onconova Therapeutics
● Horizon Pharma USA, Inc.
● Otsuka Pharmaceutical Co., Ltd.
● Syntrix Biosystems, Inc.
● Celgene Corporation
● Novartis Pharmaceuticals
● Keros Therapeutics
And Many Others

Myelodysplastic Syndrome Therapies Covered in the Report Include:
● IFN-γ (interferon gamma-1b) injection: Horizon Pharma USA, Inc.
● ASTX030: Otsuka Pharmaceutical Co., Ltd.
● SX-682: Syntrix Biosystems, Inc.
● Luspatercept: Celgene Corporation
● MBG453: Novartis Pharmaceuticals
● KER-050: Keros Therapeutics
● APR-246: Aprea Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Myelodysplastic Syndrome Current Treatment Patterns
4. Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)
7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myelodysplastic Syndrome Discontinued Products
13. Myelodysplastic Syndrome Product Profiles
14. Myelodysplastic Syndrome Key Companies
15. Myelodysplastic Syndrome Key Products
16. Dormant and Discontinued Products
17. Myelodysplastic Syndrome Unmet Needs
18. Myelodysplastic Syndrome Future Perspectives
19. Myelodysplastic Syndrome Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.